Advertisement

Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy

  • Dan Călugăru
  • Mihai Călugăru
Letter to the Editor

Dear Editor:

We would like to address several challenges that have arisen from the study by Kang et al. [1], which are specifically summarized below.

Several pertinent data are missing from the study (Table 1).
Table 1

Missing baseline data from the article by Kang et al. [1]

Variables

Anatomic lesions of neovascular maculopathy of the tAMD [choroidal neovascularization (occult/predominantly classic/minimally classic/mixed lesions), serous and/or hemorrhagic detachment of the neurosensory retina or RPE, cystic changes within neurosensory retina/inner nuclear layer, retinal hard exudates, subretinal and sub-RPE fibrovascular proliferation, disciform scar (subretinal fibrosis)]

Anatomic lesions of the PCV separately for the two subtypes of PCV (serosanguineous detachments of RPE and neurosensory retina, exudative changes, aneurismal polypoidal lesions with overlying atrophy of the pigment epithelium, abnormal branch vascular networks, vitreous hemorrhage, subretinal fibrosis, pigment...

Notes

Acknowledgements

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures. Both authors (D.C and M.C) were involved in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.

The authors have full control over the primary data, and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.

Compliance with ethical standards

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.

References

  1. 1.
    Kang EC, Choi S, Koh HJ (2017) Inner nuclear layer cystoid spaces are a poor prognosis factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol.  https://doi.org/10.1007/s00417-017-3776-9
  2. 2.
    Kawamura A, Yuzawa M, Mori R, Haruyama M, Tanaka K (2013) Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types. Acta Ophthalmol 91(6):e474–e481CrossRefPubMedGoogle Scholar
  3. 3.
    Jeong S, Sagong M (2017) Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy. Br J Ophthalmol 101(6):758–763CrossRefPubMedGoogle Scholar
  4. 4.
    Călugăru D, Călugăru M (2017) Comparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration. Am J Ophthalmol 174(2):181–182PubMedGoogle Scholar
  5. 5.
    Călugăru D, Călugăru M (2017) Long-term remission of neovascular age-related macular degeneration with as-needed anti-vascular endothelial growth factor therapy. Retina 37(9):108–110CrossRefGoogle Scholar
  6. 6.
    Călugăru D, Călugăru M (2017) Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol.  https://doi.org/10.1007/s00417-017-3797-4
  7. 7.
    Călugăru D, Călugăru M (2017) Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol.  https://doi.org/10.1007/s00417-017-3784-9
  8. 8.
    Călugăru D, Călugăru M (2017) Long-term results of pro re nata regimen of aflibercept treatment in persistent neovacular age-related macular degeneration. Am J Ophthalmol 173(1):145–146PubMedGoogle Scholar
  9. 9.
    Călugăru D, Călugăru M (2017) Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalmol 174(2):185–186PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-Napoca/RomaniaCluj-NapocaRomania

Personalised recommendations